Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Teon raises $30 million for cancer drugs

by Ryan Cross
March 5, 2021 | A version of this story appeared in Volume 99, Issue 8

 

Teon Therapeutics, a small-molecule cancer drug start-up in San Francisco, has raised $30 million in series A financing to take its lead candidate into clinical trials. The firm is developing inhibitors of G-protein-coupled receptors that detect adenosine, lipids, and lactate in the tumor microenvironment and that in turn promote tumor growth and suppress antitumor immune responses. Blocking these receptors could suppress tumor growth and help restore the immune system’s ability to fight tumors. Teon’s first program will target the adenosine A2B receptor.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.